BMS and Clovis to Study Opdivo, Rubraca Combo Treatment in Prostate, Other Cancers

BMS and Clovis to Study Opdivo, Rubraca Combo Treatment in Prostate, Other Cancers
Bristol-Myers Squibb and Clovis Oncology will collaborate to assess the combination of Opdivo (nivolumab) and Rubraca (rucaparib) in Phase 2 and 3 clinical studies in patients with different cancer types, including prostate cancer. The companies plan to launch a Phase 2 study to investigate the safety and effectiveness of the combo treatment in patients with metastatic castration-resistant

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *